Clinical trial Recruiting at 1 site Interventional Ages 3 to 80

Evaluating a new PET/CT scan for orbital tumors

Official title: Evaluating the Potential Usefulness of 18F-AlF-FAPI PET/ CT in Patients With Orbital Neoplasms and Compared With 18F-FDG PET/ CT

Run by Peking University Third Hospital · NCT06791226 · Data updated 2026-11-12

This study is testing a new type of PET/CT scan to see if it does a better job at finding orbital tumors compared to the standard scan for people who might have these tumors.

Quick facts

Study typeInterventional
Ages3 Years to 80 Years
SexAll
Enrollment50 (estimated)
SponsorPeking University Third Hospital
Academic / other
Locations1 site (Beijing, Beijing Municipality)
StatusRecruiting
StartedJuly 16, 2024
Main results expectedDecember 31, 2028
Study endsDecember 31, 2028
Registry record updatedJanuary 24, 2025
Trial IDNCT06791226 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates include patients with suspected or newly diagnosed orbital neoplasms who are scheduled for both types of PET/CT scans.

Probably not a fit

Patients who are pregnant, breastfeeding, or unable to provide informed consent will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the effectiveness of 18F-AlF-FAPI PET/CT in diagnosing primary and metastatic orbital neoplasms compared to the standard 18F-FDG PET/CT. Participants with suspected or newly diagnosed orbital tumors will undergo both imaging techniques to evaluate their diagnostic accuracy. The study will quantify tumor uptake and record the number of metastatic lesions identified by each method, calculating sensitivity, specificity, and accuracy for comparison.

Why it matters

Potential benefit: If successful, this study could improve the diagnostic accuracy for patients with orbital neoplasms, leading to better treatment decisions.

How similar studies have gone: While the use of PET/CT imaging is established, the specific application of 18F-AlF-FAPI in this context is novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. patients with suspected or newly diagnosed orbital neoplasms (supporting evidence may include MRI, CT and pathology report);
2. patients who had scheduled both 18F-FDG and 18F-AlF-FAPI PET/CT scans;
3. patients who were able to provide informed consent (signed by participant, parent or legal representative) and assent according to the guidelines of the Clinical Research Ethics Committee.

Exclusion Criteria:

1. patients with pregnancy;
2. breastfeeding;
3. the inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.

Where it's running

  • Dept. of Nuclear Medicine, Peking University Third Hospital
    Beijing, Beijing Municipality, China
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.